重视丁型肝炎研究

The research on hepatitis D should be taken seriously

丁型肝炎病毒感染是全球重要的公共卫生问题。10余年来,由于广泛的乙型肝炎疫苗免疫和移民,丁型肝炎病毒感染的流行病学发生了显著改变。丁型肝炎病毒感染可表现为联合感染或重叠感染。乙型肝炎病毒与丁型肝炎病毒合并感染的患者发生肝硬化和肝细胞癌的风险远高于乙型肝炎病毒单独感染者。新的治疗丁型肝炎药物已在研发中,部分已进入Ⅲ期临床试验,未来有望取代疗效较低的现行药物。

Hepatitis D virus(HDV)infection is an important health problem around the world.The epidemiology of HDV infection has been changed significantly over the past 10 years due to widespread hepatitis B vaccination and human migration.HDV infection can manifest as co-infection or superinfection.Patients with HBV/HDV co-infection have a significantly higher risk of liver cirrhosis and hepatocellular carcinoma than those with HBV infection alone.Research and development are being conducted for new therapeutic drugs for hepatitis D,some of which have entered phase III clinical trials.These drugs will replace the current therapies with lower efficacy.